Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06410833
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-04-29
Brief Title:
Belimumab After Rituximab in Resistant Primary Juvenile SS
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Effectiveness of Belimumab After Rituximab in Resistant Primary Juvenile Sjogrens Syndrome
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRRPJS
Brief Summary:
The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogrens syndrome
Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients
Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS
Participants will
Recieve Rituximab each week for 2-4 times until B05 or B20106L Recieve Belimumab 4 weeks after the last use of Rituximab and then every 4 weeks until week 28
Does sequential use of rituximab and belimumab reduce the activity of SS in resistant patients
Researchers will compare the disease activity before and after the treatment of sequential use of rituximab and belimumab to see if the therapy works to treat SS
Participants will
Recieve Rituximab each week for 2-4 times until B05 or B20106L Recieve Belimumab 4 weeks after the last use of Rituximab and then every 4 weeks until week 28
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None